CClaimWatch
Plaintiff counsel in 3 cases

Warren Tavares Burns

Burns Charest LLP

Address of record
900 Jackson Street, Suite 500, Dallas, TX 75202, 469-904-4550
Email
wburns@burnscharest.com
Phone
(469) 904-4550
Fax
Fax Pro Hac Vice

Contact details as filed with the court in the cases below.

3
Cases tracked
1 active · 2 settled
$657M
Plaintiff-side recovery
Disclosed settlement funds
—
Defense-side exposure
Resolved in settlements
2
Cases with values
of 3 tracked

Case history

Publicly tracked matters where this attorney is listed as counsel.

Plaintiff counselActive litigation — no settlement yet

SAS Institute Extended Stay Hotel Antitrust Class Action

A proposed class action apparently concerning antitrust and fraud allegations related to extended stay hotels. SAS Institute Inc. is identified in the docket as a party and has filed a motion to dismiss. The allegations are unproven and no settlement is indicated.

Filed
December 16, 2024
Represents
Andy Au, Karen Austin, Mignon Bacon, Sha-Quwana Boyd, Amanda Casnave, Charlotte Daniels, Trista McRae, Nadia Moreno, Andrew Rivers, Salimu Scott, Elizabeth Suriano, Matthias Will, Cynthia Wright, Christina Gonzalez, Dawn Hoffman, Regis Moeller, Simone Edmond, William Wachter, Kimbily Boyd, Kendal Morgan, Jacqueline Duncan
Plaintiff counselSettled — claims closed

Local TV Advertising Settlement

Plaintiffs claimed that broadcaster defendants engaged in a conspiracy to fix, raise, maintain, or stabilize the price levels of broadcast television spot advertising, and that sales rep firms and other entities facilitated communication between them. As a result, plaintiffs allegedly paid artificially inflated prices. The settling defendants deny all wrongdoing but have agreed to settle to avoid the cost and inconvenience of further litigation.

Settlement fund
$48M
Claim deadline
October 26, 2023
Represents
LM SAC, LLC, Southern Chevrolet Cadillac, Inc.
Plaintiff counselSettled — claims closed

EpiPen (Epinephrine) Pricing Settlement

Mylan Pharmaceuticals and Pfizer engaged in pricing and marketing practices for EpiPens that were allegedly anticompetitive. The defendants are settling claims related to these practices, with total recoveries of $609 million to class members ($345 million from Pfizer and $264 million from Mylan as of February 2022).

Settlement fund
$609M

“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.